drugset / Trial / NCT03132584
Cyclophosphamide and Alemtuzumab In Lymphoma
Phase 1
Terminated
3 enrolled
Dana-Farber Cancer Institute
Genzyme, a Sanofi Company · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab
Timeline
- Start
- 2017-07-30
- Primary completion
- 2018-01-30
- Completion
- 2018-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |